Press Release | NeoGenomics Laboratories

May 8, 2014

NeoGenomics Selected by Aurora Diagnostics as Primary Partner for Molecular, FISH, and Immunohistochemistry Testing

April 23, 2014

NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter

April 3, 2014

NeoGenomics Schedules its Q1 2014 Earnings Release for April 23, 2014

March 18, 2014

NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

February 19, 2014

NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013

January 30, 2014

NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers

January 17, 2014

NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014

January 7, 2014

NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients